Normal view MARC view

A Decision framework for the access strategy of medicines for Malaria Venture

Author: Yadav, Prashant ; Stapleton, Orla ; Van Wassenhove, Luk N.INSEAD Area: Technology and Operations Management Series: Working Paper ; 2009/41/TOM/ISIC Publisher: Fontainebleau : INSEAD Social Innovation Centre (ISIC) 2009.Language: EnglishDescription: 31 p.Type of document: INSEAD Working Paper Online Access: Click here Abstract: Many new Product Development Partnerships (PDPs) have recently been formed with the sole objective of developing drugs for neglected diseases with a high prevalence in the developing world. The Medicines for Malaria Venture (MMV) is a PDP that was established in 1999 to develop new drugs for malaria. With an initial mission to “discover” and “develop” drugs, in 2006, MMV took on the additional challenge of “delivery” of its product. This presents the organization with a series of new challenges considering the market for these drugs does not function properly. This paper identifies the main issues to be addressed in order to ensure the uptake of anti-malarial drugs and examines MMV’s role as a public private partnership in tackling these issues. It then uses stylized models to understand the need and potential benefits from MMV's involvement in these areas. This research provides MMV with the tools to develop a clear strategy to approach their role in access and delivery of anti-malarial drugs to patients in endemic countries.
Tags: No tags from this library for this title. Log in to add tags.
Item type Current location Collection Call number Status Date due Barcode Item holds
INSEAD Working Paper Digital Library
PDF Available BC008795
Total holds: 0

Many new Product Development Partnerships (PDPs) have recently been formed with the sole objective of developing drugs for neglected diseases with a high prevalence in the developing world. The Medicines for Malaria Venture (MMV) is a PDP that was established in 1999 to develop new drugs for malaria. With an initial mission to “discover” and “develop” drugs, in 2006, MMV took on the additional challenge of “delivery” of its product. This presents the organization with a series of new challenges considering the market for these drugs does not function properly. This paper identifies the main issues to be addressed in order to ensure the uptake of anti-malarial drugs and examines MMV’s role as a public private partnership in tackling these issues. It then uses stylized models to understand the need and potential benefits from MMV's involvement in these areas. This research provides MMV with the tools to develop a clear strategy to approach their role in access and delivery of anti-malarial drugs to patients in endemic countries.

Digitized

There are no comments for this item.

Log in to your account to post a comment.
Koha 18.11 - INSEAD Catalogue
Home | Contact Us | What's Koha?